

Supplemental Figure S2. Kaplan-Meier estimates for PFS (panel A) and OS (panel B) in the sensitivity analysis population according to the post-progression treatment. Blue lines indicate patients receiving any second-line therapy, whereas purple lines indicate patients receiving an anti-EGFR-based reinduction.

